Gram-negative bacteremia is a major cause of morbidity and mortality in hospitalized patients. Data to guide the duration of antibiotic therapy are limited.
Randomized, multicenter, open-label, non-inferiority trial. Inpatients with Gram-negative bacteremia, afebrile and hemodynamically stable for at least 48 hours, were randomized to receive 7 (intervention) or 14 days (control) of covering antibiotic therapy. Patients with uncontrolled focus of infection were excluded. The primary outcome at 90 days was a composite of all-cause mortality; relapse, suppurative or distant complications; and re-admission or extended hospitalization (>14 days). The non-inferiority margin was set at 10%.
We included 604 patients (306 intervention, 298 control) between January 2013 and August 2017 in three centers in Israel and Italy. The source of the infection was urinary in 411/604 (68%); causative pathogens were mainly Enterobacteriaceae (543/604, 90%). A 7-day difference in the median duration of covering antibiotics was achieved. The primary outcome occurred in 140/306 (45.8%) patients in the 7 days group versus 144/298 (48.3%) in the 14 days group (risk difference [RD] -2.6%, 95% confidence interval [CI] -10.5% to 5.3%). No significant differences were observed in all other outcomes and adverse events, except for a shorter time to return to baseline functional status in the short therapy arm.
In patients hospitalized with Gram-negative bacteremia achieving clinical stability before day 7, an antibiotic course of 7 days was non-inferior to 14 days. Reducing antibiotic treatment for uncomplicated Gram-negative bacteremia to 7 days is an important antibiotic stewardship intervention. (ClinicalTrials.gov number, NCT01737320).
1. Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in
hospitalized patients. Clin Infect Dis 2011; 52: 1232-40.
2. Corey GR, Stryjewski ME, Everts RJ. Short-course therapy for bloodstream infections in immunocompetent adults. Int J Antimicrob Agents 2009; 34: S47-51.
3. Eliakim-Raz N, Yahav D, Paul M, Leibovici L. Duration of antibiotic treatment for acute
pyelonephritis and septic urinary tract infection-- 7 days or less versus longer treatment:
systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2013; 68: 2183-91.
4. Royer S, DeMerle KM, Dickson RP, Prescott HC. Shorter Versus Longer Courses of
Antibiotics for Infection in Hospitalized Patients: A Systematic Review and Meta-Analysis. J Hosp Med 2018; 13: 336-342
5. Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy
for intraabdominal infection. N Engl J Med 2015; 372: 1996-2005.
6. Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a
systematic review and meta-analysis. Crit Care 2011; 15: R267.
7. Daneman N, Rishu AH, Pinto R, et al. 7 versus 14 days of antibiotic treatment for
critically ill patients with bloodstream infection: a pilot randomized clinical trial. Trials 2018; 19: 111.
8. Karakonstantis S, Kalemaki D. Blood culture useful only in selected patients with urinary tract infections - a literature review. Infect Dis (Lond) 2018; 50: 584-592.
9. Mandell GB, J. Dolin, R. Mandell, Douglas, And Bennett's Principles and Practice of
Infectious Diseases. Philadelphia, PA Elsevier/Saunders; 2015.
10. Daneman N, Rishu AH, Xiong W, et al. Duration of Antimicrobial Treatment for
Bacteremia in Canadian Critically Ill Patients. Crit Care Med 2016; 44: 256-64.
11. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and
management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45.
12. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Complicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry. Available from:
13. Chotiprasitsakul D, Han JH, Cosgrove SE, et al. Comparing the Outcomes of Adults
With Enterobacteriaceae Bacteremia Receiving Short-Course Versus Prolonged-Course
Antibiotic Therapy in a Multicenter, Propensity Score-Matched Cohort. Clin Infect Dis 2018; 66:172-7.
14. Park SH, Milstone AM, Diener-West M, Nussenblatt V, Cosgrove SE, Tamma PD. Short versus prolonged courses of antibiotic therapy for children with uncomplicated Gram-negative bacteraemia. J Antimicrob Chemother 2014; 69: 779-85.
15. Giannella M, Pascale R, Toschi A, et al. Treatment duration for Escherichia coli
bloodstream infection and outcomes: retrospective single-centre study. Clin Microbiol Infect 2018. [Epub ahead of print]
16. Nelson AN, Justo JA, Bookstaver PB, Kohn J, Albrecht H, Al-Hasan MN. Optimal
duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections.Infection 2017; 45: 613-20.
17. Al-Hasan MN, Nelson AN, Justo JA, Albrecht H, Kohn J, Brandon Bookstaver P. Reply to comments: duration of antimicrobial therapy for Gram-negative bacteremia secondary to urinary source of infection. Infection 2018; 46: 283-84.
18. Daneman N, Rishu AH, Xiong W et al. Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): study protocol for a pilot randomized controlled trial. Trials. 2015; 16: 173.
19. Leibovici L. Long-term consequences of severe infections. Clin Microbiol Infect 2013; 19 : 510-2.
20. Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). Clin Infect Dis. 2015; 61 :800-6.